Traynor Capital Management’s Edwards Lifesciences EW Stock Holding History

Traynor Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,729	Closed	-$289K	–	154
2019 Q4	$289K	Sell	3,729 -240	-6%	-$18.7K	0.08%	129
2019 Q3	$290K	Buy	3,969 +312	+9%	+$21.9K	0.09%	125
2019 Q2	$225K	Sell	3,657 -393	-10%	-$23.8K	0.07%	148
2019 Q1	$258K	Sell	4,050 -180	-4%	-$10.3K	0.09%	129
2018 Q4	$215K	Hold	4,230	–	–	0.09%	132
2018 Q3	$245K	Hold	4,230	–	–	0.08%	155
2018 Q2	$206K	Buy	+4,230	New	+$197K	0.08%	169
2017 Q3	–	Sell	-5,190	Closed	-$201K	–	171
2017 Q2	$201K	Buy	+5,190	New	+$189K	0.1%	142

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Traynor Capital Management's EW Position: Q1 2020 in Review

Traynor Capital Management sold out of Edwards Lifesciences (EW) in Q1 2020, closing a stake of 3,729 shares — an estimated $289K sold.

Traynor Capital Management first reported a position in EW in Q2 2017 and held it in 8 quarters. The position peaked at $290K in Q3 2019. 1,019 funds tracked by Wall St. Rank hold EW as of Q1 2020.

Traynor Capital Management reported no remaining Edwards Lifesciences position as of Q1 2020 after selling out during the quarter.
Traynor Capital Management sold 3,729 Edwards Lifesciences shares in Q1 2020, an estimated $289K.
Traynor Capital Management first reported a position in Edwards Lifesciences in Q2 2017 and held it in 8 quarters.
Traynor Capital Management's Edwards Lifesciences position peaked at $290K in Q3 2019.
1,019 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2020.

Based on Traynor Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.